Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study.

J Rheumatol

From Belgrade University School of Medicine, Belgrade, Serbia; Wojskowy Instytut Medyczny, Warsaw, Poland; Arthritis Clinic and West Tennessee Research Institute, Jackson, Tennessee; Desert Medical Advances, Palm Desert, California; Pfizer, Collegeville, Pennsylvania; Pfizer, Cambridge, Massachusetts; Janssen, Spring House, Pennsylvania, USA.

Published: December 2016

Objective: To evaluate subcutaneous SBI-087 to treat rheumatoid arthritis (RA).

Methods: A total of 210 adult patients with active RA were randomized to receive either 200 mg SBI-087 or placebo (Pbo), according to one of these patterns: SBI/Pbo/Pbo (SBI on Day 1), SBI/SBI/Pbo (SBI days 1 and 15), SBI/Pbo/SBI (SBI days 1 and 84), SBI/SBI/SBI (SBI days 1, 15, and 84), or Pbo/Pbo/Pbo (Pbo all 3 days). All patients were seropositive and taking background methotrexate. The primary endpoint was proportion of patients achieving 20% improvement from baseline at Week 16 by American College of Rheumatology criteria (ACR20). Other outcomes included 28-joint Disease Activity Score (DAS28)-C-reactive protein (CRP), physician's and patient's global assessments of disease activity (PGA and PtGA, respectively) and Health Assessment Questionnaire-Disability Index (HAQ-DI). Peripheral CD19+ B cells were measured by high-sensitivity flow cytometer. Statistical significance was set at 2-sided α 0.10 level.

Results: The SBI/SBI/SBI group demonstrated significant improvement in ACR20 and DAS28-CRP from Week 8 onward, sustained improvement in CRP levels from Week 12 onward, and significant improvements in PGA and PtGA in weeks 16 through 24, and in HAQ-DI at Week 24. The SBI/Pbo/Pbo and SBI/SBI/Pbo groups did not meet the primary endpoint but demonstrated improvements in several secondary endpoints. All treatment groups exhibited depletion of peripheral CD19+ B cells throughout the study. Overall, 61.5% of patients receiving SBI-087 and 55.0% of patients receiving Pbo reported adverse events.

Conclusion: SBI-087 effectively depleted peripheral CD20 B cells and was well tolerated. Improvements were consistently observed in the SBI/SBI/SBI group for the majority of efficacy and quality-of-life outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160146DOI Listing

Publication Analysis

Top Keywords

sbi days
12
patients active
8
rheumatoid arthritis
8
primary endpoint
8
disease activity
8
pga ptga
8
peripheral cd19+
8
cd19+ cells
8
sbi/sbi/sbi group
8
week onward
8

Similar Publications

Sepsis is a life-threatening condition that often results in severe brain injury, primarily due to excessive inflammation and mitochondrial dysfunction. This study aims to investigate the neuroprotective effects of Apelin-13, a bioactive peptide, in a rat model of sepsis-induced brain injury (SBI). Specifically, we examined the role of Apelin-13 in regulating mitophagy through the phosphatase and tensin homolog-induced putative kinase 1 (PINK1)/Parkin pathway and its impact on nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome-mediated pyroptosis and oxidative stress.

View Article and Find Full Text PDF

Background: The primary aim of this study was to compare the groups, SARS-CoV-2-positive and -negative patients, in terms of the frequency of SBI. The SARS-CoV-2-positive group was compared with the other-RVPs-positive group as a secondary evaluation in terms of serious bacterial infection (SBI).

Methods: This retrospective multicenter cohort study was conducted at four university hospitals from March 2020 to December 2021.

View Article and Find Full Text PDF

Reducing the Risk: An Evidence-Based Approach to the Febrile Infant <60 Days of Age in the Emergency Department.

Adv Emerg Nurs J

December 2024

Author Affiliations: Mid-Atlantic Emergency Medical Associates, Charlotte, North Carolina (Dr Jordan, Dr Steelman, and Ms McInnis); and UNC Charlotte School of Nursing, Charlotte, North Carolina (Dr Jordan).

Fever is the most common complaint for children of all ages who present to an emergency department (ED) for evaluation and treatment. Although most children with fever have a self-limiting viral illness, the infant less than 60 days of age with fever poses a higher risk for an underlying serious bacterial illness (SBI) including urinary tract infections, bacteremia and bacterial meningitis, or an invasive bacterial infection (IBI) including bacteremia. This case is a discussion of a high-risk febrile infant that was evaluated in the emergency department and was ultimately diagnosed with Streptococcus B meningitis.

View Article and Find Full Text PDF

Alcohol misuse is common in persons on opioid agonist maintenance treatment (OAMT). We tested the efficacy of screening and brief intervention (SBI) for harmful/hazardous alcohol use in buprenorphine/naloxone (BNX)-assisted OAMT. It was a double-blind, parallel-group, randomized trial, where 150 participants with alcohol misuse (Alcohol Use Disorder Identification Test - AUDIT 8-19) on BNX were allocated equally to receive either a single session SBI or screening and brief advice (control).

View Article and Find Full Text PDF

In this study, a wear-resistant ultra-thin wear layer was fabricated with polyurethane as an adhesive to investigate its durability for pavement applications. Its road performance was investigated based on indoor tests. First, the abrasion test was performed using a tire-pavement dynamic friction analyzer (TDFA), and the surface elevation information of the wear layer was obtained by laser profile scanning.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!